KRAS | KRAS Drug Screen | In Vivo

Unlock the full potential of your KRAS-targeting therapies by evaluating your drug candidates with our KRASmut In Vivo Screen. This platform features 60 rigorously validated PDX models, representing essential KRAS-pathway protein targets and mutations, all derived from primary patient tumors spanning 11 critical cancer types, including Ovarian, NSCLC, Pancreatic, and Sarcoma. Engineered for high clinical relevance, our models preserve key KRAS mutations such as G12C, G12D, G12R, G12V, G13D, and more, accurately reflecting patient responses. Additionally, many models have been pre-exposed to advanced KRAS-pathway cancer treatments, providing an optimal environment to assess the efficacy of your KRAS-targeting compounds.

Includes models pretreated with advanced cancer therapies post-collection and those resistant to KRAS-pathway targeted treatments and the latest immunotherapies.
Terminal tumor collections for target validation are available upon request (Snap Frozen/FFPE).
Complete model characterization (clinical data, NGS analysis, proteomics, phospho-proteomics, and more).
Several endpoint data options available including Flow Cytometry and IHC to quantify target expression and critical phenotypical changes (available upon request).
No minimum to enroll & 50% off a Standard of Care Agent arm (selected by Champions)

KRASmut In Vivo Screen

Advance your KRAS-pathway targeting therapeutic candidates using 60 carefully curated PDX mutant models derived from 11 diverse tumor types.

Biobank of PDX Models Retaining Critical KRAS Pathway Targets & Mutations

Champions' leading KRASmut In Vivo Screen showcases primary PDX models, each reflecting key clinical characteristics, mutations, and pretreatment history.